Search
                    Oklahoma Paid Clinical Trials
A listing of 859  clinical trials  in Oklahoma  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            589 - 600 of 859
        
                Oklahoma is currently home to 859 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look a...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/14/2025
            
            Locations: LifeStance Health, Moore, Oklahoma         
        
        
            Conditions: Depression
        
            
        
    
                
                                    Innovations in Genicular Outcomes Registry
                                
            
            
        Recruiting
                            
            
                The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                05/12/2025
            
            Locations: Oklahoma Surgical Hospital, Tulsa, Oklahoma         
        
        
            Conditions: Knee Osteoarthritis
        
            
        
    
                
                                    S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
                                
            
            
        Recruiting
                            
            
                This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/12/2025
            
            Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma         
        
        
            Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
        
            
        
    
                
                                    The Interaction of Body Composition, Sex Hormones and Exercise in Men
                                
            
            
        Recruiting
                            
            
                The overall objective of this project is to advance understanding of the causes of normal weight obesity (NWO) in men, namely the hormone profile and related potential mediating mechanisms, and the efficacy of different modes of exercise to restore body composition and cardiometabolic health in this population.             
        
        
    Gender:
                MALE
            Ages:
                Between 18 years and 79 years
            Trial Updated:
                05/09/2025
            
            Locations: Oklahoma State University, Stillwater, Oklahoma         
        
        
            Conditions: Normal-weight Obesity
        
            
        
    
                
                                    Clinical Performance Evaluation of the Artificial Intelligence (AI)/ Machine Learning (ML) Technologies Utilized by the Origin Medical EXAM ASSISTANT
                                
            
            
        Recruiting
                            
            
                A multicenter study will be conducted to assess the role of the AI/ML technologies of Origin Medical EXAM ASSISTANT (OMEA) in interpreting first-trimester fetal ultrasound examinations (11 weeks 0 days - 13 weeks 6 days). The performance of the AI-based system will be compared against the ground truth provided by an independent reading panel of maternal-fetal medicine physicians.             
        
        
    Gender:
                FEMALE
            Ages:
                18 years and above
            Trial Updated:
                05/09/2025
            
            Locations: The Nest 4D Ultrasound LLC, DBA InFocus Ultrasound DBA Little Peanut 4D Ultrasound, Norman, Oklahoma         
        
        
            Conditions: To Validate the Clinical Performance of AI/ML Technologies in First-trimester Pregnant Participants, First Trimester Pregnancy
        
            
        
    
                
                                    Optimizing Body Mass Index (BMI) With TCMCB07, The Paradox Trial
                                
            
            
        Recruiting
                            
            
                This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 100 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-optimal BMIs (18 to ≤ 29 kg/m2). Treatment will begin on the same day as the start of cancer chemotherapy and continue during the first 28 days of cytotoxic therapy with a goal of preserving muscle and...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/09/2025
            
            Locations: Investigative Site, Oklahoma City, Oklahoma         
        
        
            Conditions: Cachexia; Cancer
        
            
        
    
                
                                    A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)
                                
            
            
        Recruiting
                            
            
                The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).             
        
        
    Gender:
                ALL
            Ages:
                50 years and above
            Trial Updated:
                05/08/2025
            
            Locations: Retina Vitreous Center, Edmond, Oklahoma         
        
        
            Conditions: Geographic Atrophy
        
            
        
    
                
                                    DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
                                
            
            
        Recruiting
                            
            
                The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.             
        
        
    Gender:
                ALL
            Ages:
                Between 9 years and 14 years
            Trial Updated:
                05/07/2025
            
            Locations: The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma         
        
        
            Conditions: Diabetes Mellitus Type 2, Childhood-Onset
        
            
        
    
                
                                    A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
                                
            
            
        Recruiting
                            
            
                In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants.
The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is:
-...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/07/2025
            
            Locations: Hightower Clinical, Oklahoma City, Oklahoma         
        
        
            Conditions: Lupus Erythematosus, Systemic
        
            
        
    
                
                                    Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
                                
            
            
        Recruiting
                            
            
                The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 64 years
            Trial Updated:
                05/07/2025
            
            Locations: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma         
        
        
            Conditions: Post Operative Surgical Site Infection
        
            
        
    
                
                                    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
                                
            
            
        Recruiting
                            
            
                This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/06/2025
            
            Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma         
        
        
            Conditions: Colon Cancer, Metastatic Colon Cancer
        
            
        
    
                
                                    A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 55 years
            Trial Updated:
                05/06/2025
            
            Locations: Tekton Research, Inc, Edmond, Oklahoma         
        
        
            Conditions: Epstein-Barr Virus Infection
        
            
        
    